Showing results (41-50 of 48) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 48 results.
Infection and Drug Resistance|March 16, 2026
Enhanced Spread of Carbapenem-Resistant Pseudomonas aeruginosa in ICU Environment During a COVID-19 Upsurge Period in ChinaHanming Ni, Hong Sun, Zengzeng Zhang, et al.
The Journal of Infection|November 3, 2024
Clinical characteristics and prognosis of bloodstream infections with carbapenem-resistant Gram-negative organisms in patients with hematological malignancies: A multicenter case-control study in ChinaJunxin Zhou, Jian Sun, Shanshan Lu, et al.
Antimicrobial Agents and Chemotherapy|March 6, 2025
Clinical outcomes and pharmacokinetics/pharmacodynamics of intravenous polymyxin B treatment for various site carbapenem-resistant gram-negative bacterial infections: a prospective observational multicenter studyZhenwei Yu, Huangdu Hu, Xiaofen Liu, et al.
Frontiers in Pharmacology|January 2, 2023
Pharmacokinetics/pharmacodynamics of polymyxin B in patients with bloodstream infection caused by carbapenem-resistant Klebsiella pneumoniaeZhenwei Yu, Xiaofen Liu, Xiaoxing Du, et al.
Ebiomedicine|March 20, 2026
Clinical characteristics and molecular epidemiology of KPC-NDM co-producing carbapenem-resistant Klebsiella pneumoniae in China: a multicentre retrospective case-control studyXi Li, Xinhong Han, Xinyan Tang, et al.
Nature Communications|February 6, 2026
Heterogeneous multicopy of blaCTX-M variants on the same plasmid enhances evolutionary adaptability in clinical Klebsiella pneumoniaeRui Weng, Jingyi Zhu, Xueqing Wu, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|May 3, 2026
Comparative between eravacycline and best available therapy in carbapenem-resistant Acinetobacter baumannii HAP/VAP in China: a retrospective real-world multicenter cohort studyHuangdu Hu, Yifeng Luo, Meijun Song, et al.
ACS Medicinal Chemistry Letters|January 8, 2019
Discovery of Orally Bioavailable and Liver-Targeted Hypoxia-Inducible Factor Prolyl Hydroxylase (HIF-PHD) Inhibitors for the Treatment of AnemiaPing Liu, Liping Wang, Byron G DuBois, et al.
Pageof 5